breast cancer
Conditions
Interventions
Group A/Group B:Group A (distance between primary glandular tumor and skin>1cm): Preoperative neoadjuvant local tumor enhanced irradiation with DT10GY/1F/d.
Group B (primary breast tumor distance from
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age >=18 years, <=70 years; 2. ECOG PS < 2; 3. Preoperative puncture pathology confirmed the diagnosis of invasive breast cancer; 4. Stage II-III patients with clinical stage T2-3N0M0 or T1-3N1-2M0 or T1-3N3M0. 5. The patient is scheduled to receive standard neoadjuvant therapy. 6. Breast-conserving or potentially breast-conserving, willing to undergo breast-conserving surgery. 7. No previous history of other malignant tumors, except skin basal cell carcinoma; 8. Informed consent was signed before the study began.
Exclusion criteria
Exclusion criteria: 1. Clear clinical or imaging evidence of metastatic disease; 2. People who do not need neoadjuvant therapy in the early stage; 3. T4: including inflammatory breast cancer; 4. T0: patients with occult breast cancer; 5. No possibility of breast-conserving treatment; 6. Refuse breast-conserving surgery patients; 7. Male breast cancer patients; 8. Complicated with serious heart, lung, liver, kidney, hematopoietic system and nervous system diseases, mental diseases; 9. Previous history of chest radiothe; 10. With scleroderma or active lupus erythematosus and other autoimmune diseases; 11. Pregnant and lactating patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of grade 3 short-term incision complications; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cosmetic Results;Pathologic Complete Response,pCR;rates of Local Recurrence,LR;rates of Local Regional Recurrence,LRR;disease free survival,DFS;Overall Survival,OS;Quality of life assessment;Treat toxic side effects; | — |
Countries
China
Contacts
Public ContactXia Zhou
Zhejiang Cancer Hospital
Outcome results
None listed